HIV, Hepatitis B and C among people who inject drugs: high prevalence of HIV and Hepatitis C RNA positive infections observed in Delhi, India

被引:36
作者
Saraswati, Lopamudra Ray [1 ]
Sarna, Avina [1 ]
Sebastian, Mary Philip [1 ]
Sharma, Vartika [1 ]
Madan, Ira [2 ]
Thior, Ibou [3 ]
Pulerwitz, Julie [3 ,4 ]
Tun, Waimar [4 ]
机构
[1] Populat Council, India Habitat Ctr, New Delhi 110003, India
[2] Sahara Ctr Residential Care & Rehabil, New Delhi, India
[3] ARISE Project, Washington, DC USA
[4] Populat Council, Washington, DC USA
关键词
HIV; Hepatitis B; Hepatitis C; HIV-HCV co-infection; People Who Inject Drugs (PWID); India; LIVER-DISEASE; VIRUS COINFECTION; RISK BEHAVIORS; USERS; CHENNAI; HCV; EPIDEMIOLOGY; MORTALITY; SERVICES; FIBROSIS;
D O I
10.1186/s12889-015-2003-z
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: India has large PWID (persons who inject drugs) population estimated at 177,000. PWIDs are at high risk for HIV, Hepatitis B (HBV) and Hepatitis C (HCV) infections. We report the prevalence of HIV, HBV and HCV infections and correlates of HIV-HCV co-infection among male PWIDs in Delhi. Methods: 3748 male PWIDs were recruited for a longitudinal HIV incidence study. Participants were tested for HBV and HCV infections at their first follow-up visit (FV1) using serum HBV-surface antigen, and HCV-antibody tests followed by HCV RNA PCR, respectively. All PWIDs who were HIV-negative at enrollment, were re-tested for HIV at FV1. Multinomial logistic regression was employed to identify predictors of HIV, HCV and HIV-HCV co-infection. Results: Overall prevalence of HIV, HBV and HCV among 2,292 participants tested at FV1 was 25.9 %, 9.7 % and 53.7 %, respectively. 6.4 % of the participants had HIV mono-infection, 34.1 % had HCV mono-infection, and 19.6 % had HIV-HCV co-infection. 26 % of HIV-positive participants without HCV were HBsAg positive. In the regression model, having practiced at least one risky injection in the past month (relative risk ratio (RRR): 1.38; 95 % CI: 1.01-1.89) and not knowing his own HIV status (RRR: 1.65, 95 % CI: 1.25-2.17) were independent predictors for HIV-HCV co-infection. Longer duration of drug injections was associated with a higher likelihood of HCV mono-infection (2-5 years RRR: 2.13; 6-10 years RRR: 2.74; >= 11 years RRR: 3.14) and HIV-HCV co-infection (2-5 years RRR: 5.14; 6-10 years RRR: 8.53; > 11 years RRR: 8.03). Higher frequency of injection days/month was associated with a higher likelihood of HCV mono-infection (<= 10 days/month RRR: 1.61; 11-20 days/month RRR: 3.15; 21-30 days/month RRR: 3.47) and HIV-HCV co-infections (<= 10 days/month RRR: 2.26; 11-20 days/month RRR: 3.46; 21-30 days/month RRR: 4.83). Conclusions: We report a high prevalence of HIV, HCV and HIV-HCV co-infection among male PWIDs in Delhi. A tenth of the participants were HBsAg positive. Targeted Intervention programs should make HBV/HCV testing, prevention and care more accessible for PWIDs.
引用
收藏
页数:11
相关论文
共 36 条
[1]  
Ambekar A., 2012, ASS DRUG USE PATTERN
[2]  
[Anonymous], 2021, NAT OP GUID ART SER
[3]   Seroprevalence of anti-hepatitis C virus (anti-HCV) antibody and HCV-related risk in injecting drug users in northern India: Comparison with non-injecting drug users [J].
Basu, Debasish ;
Kumar, Vineet ;
Sharma, Arun Kumar ;
Barnwal, Pawan Kumar ;
Mattoo, Surendra Kumar .
ASIAN JOURNAL OF PSYCHIATRY, 2013, 6 (01) :52-55
[4]  
Baveja U K, 2003, Indian J Med Microbiol, V21, P280
[5]   Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection [J].
Bica, I ;
McGovern, B ;
Dhar, R ;
Stone, D ;
McGowan, K ;
Scheib, R ;
Snydman, DR .
CLINICAL INFECTIOUS DISEASES, 2001, 32 (03) :492-497
[6]  
Braunwald E., 2001, Harrison's Principles of Internal Medicine, V2
[7]  
Chelleng PK, 2008, INDIAN J MED RES, V128, P640
[8]  
Crofts N, 2001, Aust Fam Physician, V30, P420
[9]  
CROFTS N, 2001, HEPATITIS C AUSTR PE
[10]  
Devi Kh. Sulochana, 2005, Journal of Communicable Diseases, V37, P73